Background: In response to DNA damage, cells undergo either cell-cycle arrest or apoptosis, depending on the extent of damage and the cell's capacity for DNA repair. Cell-cycle arrest induced by double-stranded DNA breaks depends on activation of the ataxia-telangiectasia (ATM) protein kinase, which phosphorylates cell-cycle effectors such as Chk2 and p53 to inhibit cell-cycle progression. ATM is recruited to double-stranded DNA breaks by a complex of sensor proteins, including Mre11/Rad50/Nbs1, resulting in autophosphorylation, monomerization, and activation of ATM kinase. Results: In characterizing Aven protein, a previously reported apoptotic inhibitor, we have found that Aven can function as an ATM activator to inhibit G2/M progression. Aven bound to ATM and Aven overexpressed in cycling Xenopus egg extracts prevented mitotic entry and induced phosphorylation of ATM and its substrates. Immunodepletion of endogenous Aven allowed mitotic entry even in the presence of damaged DNA, and RNAi-mediated knockdown of Aven in human cells prevented autophosphorylation of ATM at an activating site (S1981) in response to DNA damage. Interestingly, Aven is
Introduction
Entry into mitosis, driven by Cdc2/Cyclin B, can be inhibited after DNA damage by DNA-responsive checkpoints [1, 2] . These signaling pathways employ DNA-damage sensors and transducers to inhibit cell-cycle effectors [3] . To prevent mitotic entry, checkpoint pathways target the critical Cdc2 regulators, Wee1 and Cdc25 [4] [5] [6] [7] , which inhibit and activate Cdc2/Cyclin B, respectively [1, 2, 8] . When checkpoints are operative, Chk1/ Chk2 kinases phosphorylate Wee1 and Cdc25, inducing activation and inhibition, respectively, of the downstream molecules [6, 9] . Cdc25 is phosphorylated and inhibited by Chk1/ Chk2-mediated phosphorylation at S287 (Xenopus numbering), which promotes docking of 14-3-3 [10] [11] [12] [13] [14] . Cdc25 activation depends upon active 14-3-3 removal and subsequent PP1-mediated S287 dephosphorylation [15] [16] [17] .
Activation of Chk1/Chk2 requires DNA-damage-mediated activation of upstream members of the phosphoinositide-3-kinase-related kinases (PIKKs), ATM and ATR [11, [18] [19] [20] [21] . In the case of double-stranded DNA breaks, a complex of proteins, including Mre11, Rad50, and Nbs1 (the MRN complex), accumulates at DNA-damage sites to form foci. ATM is then recruited to the MRN complex, where it autophosphorylates at S1981 and is converted from an inactive dimer into an active monomer [22] [23] [24] [25] [26] . It is likely that there are other, as-yet-unidentified factors that participate in ATM regulation.
A variety of cellular processes have been reconstituted in extracts prepared from Xenopus eggs [27] [28] [29] . Cycling egg extracts [30] , which oscillate between S and M phases of the cell cycle, can recapitulate DNA-damage-responsive checkpoints in vitro; addition of annealed oligonucleotides mimicking damaged DNA prevents M phase entry, arresting extracts with inactive Cyclin B/Cdc2 complexes [18, 31, 32] . Incubation of egg extracts on the bench for 4-6 hr results in cytochrome c release from mitochondria and caspase activation [33] [34] [35] . These cycling and apoptotic properties of the Xenopus egg extracts make them well-suited for the analysis of factors implicated in cell-cycle progression or apoptosis.
We wished to use egg extracts to analyze the function of a previously reported apoptotic inhibitor, Aven. Human Aven was originally identified as an interactor of the anti-apoptotic protein Bcl-x L . Aven mRNA was detected in all adult tissues but was most abundant in heart, skeletal muscle, kidney, liver, pancreas, and testis. Although the predicted molecular weight of Aven is 38.6 kDa, the apparent molecular weight of Aven derived from HeLa cells, where it can be found in both cytoplasmic and nuclear fractions, is 55 kD. Aven overexpression is reported to be associated with poor prognosis in childhood acute lymphoblastic leukemia [36] [37] [38] [39] . In addition to its interaction with Bcl-x L , Aven is reported to interact with and inhibit Apaf-1 oligomerization, which is required for activation of caspase-9 [40, 41] . The molecular mechanism underlying the ability of Aven to impede Apaf-1 oligomerization and the significance of Aven's association with Bcl-xL are not clear. Moreover, the possibility that Aven might have additional functions has not been explored.
We have now found that Aven protein is a potent activator of ATM, critical for its DNA-damage-induced activation. Aven overexpression in cycling egg extracts induced phosphorylation of Figure 1 . Aven Overexpression Delays Mitotic Entry (A) Cycling Xenopus egg extracts were supplemented with mRNA encoding full-length human Aven (hAven) or an equal volume buffer control. Samples were withdrawn at the indicated times and assayed for their ability to phosphorylate histone H1 in the presence of [g-32 P] ATP. (B) mRNA encoding hAven, DN72hAven or Xenopus b-globin (x-ßGlobin), or buffer control were added to cycling Xenopus egg extracts. Aliquots of extracts were withdrawn at the indicated times and assayed as in (A). (C and D) His-DN72hAven protein or GST control was added to interphase extracts and incubated for 30 min. After the addition of nondegradable CyclinB1, aliquots were taken at the indicated times (C) for visualization of nuclear-envelope breakdown and chromatin condensation by fluorescence microscopy (Hoechst DNA stain) and (D) to assay histone H1 phosphorylation. (C) Bottom: represents the average of three replicates. (E) Cycling extracts were incubated with mRNA encoding Xenopus Aven (xAven) or buffer, and aliquots were taken at the indicated times and assayed as in (A). (F) Forty stage-VI oocytes were injected with mRNAs encoding x-ßGlobin, xAven, or hAven. After 12 hr, oocytes were treated with progesterone and scored for germinal-vesicle breakdown (GVBD). Data shown in this and all subsequent figures are the result of at least three repetitions.
ATM substrates independent of DNA damage, and depletion of Aven abrogated G2/M arrest in response to DNA damage. Similarly, RNAi knockdown of Aven in mammalian cells dampened DNA-damage-induced ATM activation. Phosphorylation of Aven by ATM in a positive feedback loop appears to be required for its full potency as an ATM activator. These data implicate the apoptotic regulator Aven as an integral component of the DNA-damage-responsive-checkpoint pathway.
Results

Aven Inhibits Entry into Mitosis
To further analyze the apoptotic function of Aven, we wished to overexpress Aven protein and determine its effects on caspase activation in Xenopus egg extracts. However, when we added excess mRNA encoding human Aven protein (approximately doubling the endogenous Aven concentration of 80 nM) to cycling egg extracts, we found that Aven had a profound effect on cell-cycle progression. The extracts expressing excess Aven either failed to enter mitosis or was significantly delayed in mitotic entry, as evidenced by a dampening of histone H1 kinase activation and an inhibition of nuclear-envelope breakdown and chromatin condensation ( Figures 1A and 1B and data not shown) . To confirm that the protein product of Aven mRNA was responsible for cellcycle inhibition, recombinant His-tagged human Aven protein lacking its Gly-rich N terminus (His-DN72), which posed difficulty for protein purification, was added to interphase egg extracts treated with recombinant Cyclin B to drive mitotic entry. His-DN72 Aven protein prevented nuclear-envelope breakdown, chromatin condensation, and activation of Cdc2/Cyclin B ( Figures 1C and 1D ). Similar results were obtained when Aven mRNA lacking codons 2-72 was added to cycling extracts ( Figure 1B) , indicating that the Gly-rich N-terminal region was not required for the cell-cycle arrest. To demonstrate that Xenopus Aven, which shares 42% amino acid sequence identity with human Aven, could also inhibit mitotic entry, we cloned the Xenopus Aven cDNA ( Figure S1 , available online) and repeated our experiments analyzing the effects of fulllength Xenopous Aven overexpression on M-phase entry. As shown in Figure 1E , Xenopus Aven acted similarly to human Aven in retarding mitotic entry. To assay the effects of Aven in an intact cell, we tested whether Aven overexpression would impede progesterone-induced oocyte maturation (progression through G2/M). Expression of either Xenopus or human Aven mRNAs, but not of control Xenopus b-globin mRNA, markedly delayed M-phase entry in oocytes ( Figure 1F ).
Aven Inhibits Activation of Cdc2/Cyclin B Aven's ability to inhibit histone H1-directed kinase activity suggested that Aven might inhibit Cdc2 directly. However, as shown in Figure 2A , addition of Aven protein to purified Cdc2/Cyclin B had no effect on Cdc2 kinase activity, even at protein levels as high as 320 nM. Cdc2 activity is controlled by Cyclin levels [42, 43] and through inhibitory Y15 phosphorylation of Cdc2 [1, 2] . Cyclin B protein synthesis was unaffected by Aven (data not shown). In contrast, Cdc2 dephosphorylation on Y15, which occurred on schedule in control extracts, was absent in the Aven-supplemented extracts, consistent with a role for Aven as a mitotic inhibitor ( Figure 2B ).
Maintenance of Cdc2 Y15 phosphorylation could result from sustained activation of Y15-directed kinases (Wee1 and Myt1), from inhibition of the Y15-directed phosphatase, Cdc25, or both [1] . Activation of Cdc25 at mitotic entry requires T138 phosphorylation, which promotes removal of bound 14-3-3 and allows the reversal of inhibitory S287 phosphorylation on Cdc25 [15] . To determine whether Aven could modulate Cdc25, we monitored Cdc25 modifications in the presence and absence of increased Aven protein. As shown in Figure 2C , in the presence of Aven protein, T138 phosphorylation was not observed, Cdc25 remained 14-3-3-bound, and S287 remained phosphorylated, consistent with a role for Aven in controlling upstream factors that regulate Cdc25 ( Figure 2C ). Moreover, expression of an S287A mutant Cdc25, but not of wild-type (WT) Cdc25, in cycling extracts could override the effects of Aven addition, allowing Cdc2 Y15 dephosphorylation despite Aven overexpression ( Figure 2D ).
Although Aven impinged on Cdc25 activation, this did not preclude a role for Aven in the activation of Wee1 (or Myt1). In unperturbed extracts, Wee1 and Myt1 activity is high during interphase and drops at mitotic entry to allow Cdc2 activation [44] . Remarkably, addition of recombinant Aven to extracts already in mitosis allowed suppression of Cdc2 activity and rephosphorylation of Y15 ( Figures 2E and 2F ). Given that Wee1 and Myt1 are normally turned off in mitotic extracts and Cdc2 was fully dephosphorylated prior to Aven addition, these results strongly suggest that Aven can modulate both the Cdc25 and the Wee1 and Myt1 arms of the Cdc2-regulatory pathway.
Aven Interacts with and Activates ATM Because Aven appeared to control Cdc25 at known points of DNA-responsive-checkpoint regulation (T138 and S287) and because both Wee1 and Cdc25 might be modulated downstream of Aven, we speculated that Aven might be an upstream regulator of factors that normally participate in DNAresponsive-checkpoint signaling. In support of this, we found that both the inhibitor of Chk kinases, UCN-01, and the ATM/ ATR inhibitor, caffeine, could override the ability of Aven to induce cell-cycle arrest prior to mitotic entry ( Figures 3A and 3B ).
Using Aven residues 1-289 as bait in a yeast two-hybrid screen of a cDNA library from 3-week-old rat brain (provided by Paul Worley; note that the C-terminal domain was eliminated because it had the intrinsic ability to activate transcription), we identified the C-terminal kinase domain (wresidues 2500-3000) of ATM kinase as a potential Aven interactor. The binding of Aven both to the kinase domain and to full-length ATM was confirmed by coimmunoprecipitation experiments in transfected mammalian cells. Furthermore, both full-length Aven and DN72-Aven interacted with ATM ( Figure 3C and data not shown). Moreover, GST-Aven-coupled glutathione beads retrieved ATM from Xenopus interphase extracts, and this band disappeared upon immunodepletion of ATM (Figure 3D ). Given these findings, we examined whether Aven requires ATM for inhibition of the cell cycle. Aven-induced arrest was markedly abrogated when ATM had been immunodepleted from egg extracts, suggesting that Aven acts, at least in part, through ATM activation ( Figure 3E) . Moreover, as shown in Figure 3F , expression of human Aven in egg extracts promoted an electrophoretic shift in Chk2 (indicative of activation) commensurate with the shift promoted by DNA bearing double-stranded breaks (DSB). The addition of either human Aven or DSB DNA to extracts also promoted commensurate phosphorylation of p53 at a known site of ATM-catalyzed phosphorylation (S15) ( Figure S2 ). We also found that the ability of endogenous Aven to coimmunoprecipitate with ATM from HeLa cell nuclear extracts was markedly increased by pretreatment of cells with the radiomimetic drug neocarzinostatin (NCS) ( Figure 3G ; although some ATM signal is seen in mock immunoprecipitates, this signal is NCS-insenstive and substantially weaker than that seen in the Aven precipitate from NCS-treated cells). Moreover, Aven could bind to plasmid DNA only after it had been linearized, suggesting that Aven might have affinity for DSB DNA ( Figure 3H ).
Although Aven could promote phosphorylation of ATM substrates and induce cell-cycle arrest, it was not clear whether Aven acted upstream of ATM to promote its activation rather than at the level of the substrate(s). To address this, we examined phosphorylation of ATM itself at S1981, a site that is auto (or trans)-phosphorylated in response to DNA damage. Because it was possible that Aven addition promoted DNA damage to trigger ATM activation indirectly, we examined S1981 phosphorylation in extracts lacking DNA but supplemented with Aven. As shown in Figure 3I , Aven addition promoted endogenous ATM S1981 phosphorylation, as seen after the addition of DSB DNA. Moreover, this S1981-phosphorylation signal was overridden by caffeine and reduced by ATM depletion, consistent with Aven's ability to promote ATM autophosphorylation ( Figure 3I and Figure S3 ). Virtually identical results were obtained when a recombinant fragment that includes the ATM-S1981 site (GST-ATM aa1905-2100) was added to extracts as a trans substrate of endogenous ATM ( Figure S4 ). These data demonstrate that Aven addition to egg extracts triggers ATM activation to promote G2/M arrest. Furthermore, Aven overexpression acted synergistically with DSB DNA in Xenopus egg extracts or the radiomimetic drug neocarzinostatin (NCS) to induce ATM S1981 phosphorylation in Hela cells ( Figures 3J and 3K, respectively) , consistent with the notion that Aven contributes to ATM activation in response to DNA damage.
Aven is Required for DNA-Damage-Induced Inhibition of Mitotic Entry
Although exogenous Aven appeared to promote ATM activation in the absence of DNA damage, we wished to determine whether Aven was required for activation of ATM by endogenous DNA-responsive-checkpoint pathways. Addition of (B) Interphase extracts were incubated with His-DN72hAven protein or His-GST control for 30 min. Nondegradable cyclinB1 was then added to the extracts, and aliquots were taken at the indicated times for immunoblotting with anti-pCdc2Y15. (C) His-DN72hAven protein, together with GST-Cdc25 coupled to glutathione beads, was incubated in interphase egg extract for 30 min. After the addition of nondegradable CyclinB1, GST-Cdc25 beads were retrieved and washed at the indicated times and immunoblotted with anti-14-3-33 antibody. In addition, aliquots were taken at the same time points and immunoblotting was performed with anti-pCdc25T138, anti-pCdc25S287, or anti-pCdc2Y15 antibody. (D) Cycling extracts were incubated with mRNA encoding hAven or with hAven and WT Cdc25 or Cdc25S287A. Samples were taken at the indicated times and immunoblotted with anti-pCdc2Y15 antibody. (E and F) His-DN72hAven protein or GST control protein was added to mitotic extracts; aliquots were taken at the indicated times and assayed for their ability to phosphorylate histone H1 or immunoblotted with anti-pCdc2Y15 antibody. S-labeled Chk2 6 caffeine (5 mM) for 1 hr. Aliquots were resolved by SDS-PAGE, and Chk2 electrophoretic mobility was examined with the use of a phosphoimager. (G) HeLa cells treated with or without NCS (200 ng/ml) for 1hr were harvested to make nuclear fractions. Rabbit anti-Aven antibody or control IgG immunoprecipitates were immunoblotted with the indicated antibodies. (H) Circular pGEX-KG-Emi2 or Not-I cut linear pGEX-KG-Emi2 plasmid was incubated in the interphase extracts for 30min. Anti-Xenopus Aven antibody or control IgG was used for immunoprecipitation and washed immunoprecipitates were used as PCR templates to detect DNA binding to Xenopus Aven. (I) Cycling extracts were supplemented with buffer control, DSB DNA, or mRNA encoding full-length hAven, DN72hAven, or full-length xAven +/2 caffeine (5mM) for 1hr. Samples were taken and immunoblotted with anti-pATM S1981 antibody. (J) Top panel: buffer control, 10 ng of (dA-dT) 70 , 10 ng of (dA-dT) 70 with mRNA encoding DN72hAven, or mRNA encoding DN72hAven was added to cycling extracts. After 1hr, samples were immunoblotted with the indicated antibodies. Bottom panel: the amount of pATM S1981 was quantified, normalized, and plotted. Error bars represent the standard deviation of three replicate experiments. (dA-dT) 70 promotes robust activation of DNA-responsive checkpoints in egg extracts [32] , resulting in stabilization of inhibitory Y15 phosphorylation of Cdc2. In contrast, immunodepletion of endogenous Aven protein allowed entry (albeit delayed) into mitosis even in the face of checkpoint activation ( Figure 4A ). To rule out the possibility that removal of Aven codepleted an associated protein that allowed DNA-damagecheckpoint override, Aven was added back to extracts after immunodepletion. When mRNA for either human or Xenopus Aven was added back to Aven-depleted extracts, (dA-dT) 70 -induced-checkpoint activation was restored ( Figure 4B) .
In response to DNA damage, ATM is phosphorylated at S1981 and is localized in foci, which can be detected as punctate staining by immunofluorescence [25, 45] . To examine the role of Aven in checkpoint-induced ATM activation in a mammalian system, we utilized RNAi interference (pooled oligonucleotides) to knock down the expression of endogenous human Aven in HeLa cells and monitored the activation status of ATM upon addition of the radiomimetic drug neocarzinostatin (NCS). As shown in Figure 4C , NCS-treated HeLa cells displayed discrete foci of phospho-ATM that colocalized with phospho-H2AX. Remarkably, the phospho-ATM signal was absent from cells ablated for Aven by RNA interference (Figure 4D ). These data strongly suggest that ATM could not be activated or that the activation could not be sustained in the absence of Aven. These findings were confirmed by immunoblotting of pATM S1981, given that depletion of Aven abolished detectable autophosphorylation on S1981 of ATM in response to DNA damage ( Figure 4E ). To further validate these findings, individual siRNAs from the pool were used to knock down Aven; two different oligonucleotides that decreased Aven levels dampened the appearance of S1981 phosphorylation in response to NCS ( Figure 4F ; note that the Aven knockdown in these experiments is not complete). These data reinforce the conclusion that Aven is required for the linking of DNA damage to ATM activation.
ATM Phosphorylates and Activates Aven in a Positive Feedback Loop
Positive and negative feedback loops are common in cellcycle-regulatory networks [1, 2, 16, 46, 47] . Hence, we sought to determine whether Aven, in addition to its role as a modulator of the ATM pathway, might also be a substrate of ATM. Indeed, activation of the DNA-damage checkpoint with DSB DNA, but not of the replication checkpoint with aphidicolin-treated nuclei, enhanced phosphorylation of Aven in egg extracts, an effect that could be abrogated by the addition of caffeine ( Figure 5A ); the addition of KU55933, an ATM-specific inhibitor ( Figure S5) ; or the immunodepletion of ATM ( Figure S6 ). In addition, active ATM immunoprecipitated from 293T cells could phosphorylate Aven in vitro, and this phosphorylation was largely inhibited by treatment with wortmannin, an inhibitor of PI3K-family kinases ( Figure 5B ). Moreover, when ATM was immunodepleted from extracts, Aven phosphorylation by ATM immunoprecipitates was largely abrogated ( Figure S7 ).
ATM typically phosphorylates serine residues followed by glutamine (SQ sites) [48] , and analysis of the amino acid sequence of human Aven revealed four such motifs located at residues S135, 153, 268, and 308. To study the potential effect of ATM-mediated phosphorylation on Aven function, we mutated these four SQ sites to AQ and analyzed the phosphorylation status of the resulting mutant. As shown in Figure 5C and Figure S5 , DSB DNA enhanced Aven phosphorylation over time, and mutation of all four putative ATM-phosphorylation sites largely eliminated the DSB-DNA-enhanced phosphorylation of Aven (though basal phosphorylation remained). We performed mass spectrometry on recombinant Aven protein that had been dipped into egg extracts treated with or without DSB DNA and identified S135 and S308 as conserved sites of phosphorylation ( Figure 5D and Figure S9 ). To confirm the significance of these two phospho-SQ sites, we mutated these to AQ and performed an in vitro ATM kinase assay using ATM immunoprecipitated from Xenopus egg extracts. We found that mutating S135 and S308 sites to Alanine largely dampened Aven's phosphorylation by ATM (though some phosphorylation remained, due to either a contaminating kinase or an unidentified ATM-phosphorylation site). However, it is noteworthy that we did not observe any additional decrease in phosphorylation when we changed S153 or S268 to Alanine ( Figure 5E and Figure S10 ), consistent with our mass-spectrometric identification of phospho-S135 and -S308 following ATM activation. To analyze the effects of Aven phosphorylation, we added mRNA encoding either WT or nonphosphorylatable (S135, 308A) mutant Aven to cycling egg extracts and monitored mitotic entry. Mutant Aven protein was partially active, but it failed to maintain the cell-cycle arrest observed with similar levels of WT Aven ( Figure 5F ). These data suggest that Aven overexpression can activate ATM and that Aven phosphorylation in a positive feedback loop enforces Aven activity, making it a more potent ATM activator.
Discussion
The results described here implicate Aven as a key regulator of the G2/M DNA-damage checkpoint. Aven's ability to prevent M-phase entry stems from its ability to activate ATM to promote phosphorylation and activation of cell-cycle inhibitors (e.g., Chk2) controlling Cdc2/Cyclin B (see model, Figure 6 ). Precisely how Aven is engaged after DNA damage remains to be determined, but it is clear that the absence of Aven impairs checkpoint-mediated ATM function.
Aven-Mediated ATM Activation
Because Aven interacted with ATM and induced ATM S1981 phosphorylation, Aven protein might initiate activation of ATM (i.e., recruitment to sites of DNA damage, monomerization, and autophosphorylation). Although we did not detect Aven interaction with MRN complex, we have noticed that Aven protein binds efficiently to restriction-enzyme-digested plasmids but not to intact plasmids added to egg extracts. In addition, the endogenous Aven-ATM interaction was increased after DNA damage, suggesting that Aven might be involved in ATM recruitment to sites of double-stranded DNA breaks or that double-stranded breaks provide a platform for Aven-mediated ATM activation. Alternatively, Aven might inhibit ATM S1981 dephosphorylation, thereby interfering with maintenance of ATM activity. Both PP2A and Wip1 dephosphorylate ATM S1981 [49, 50] . However, we have not observed any direct interaction of Aven with PP2A or Wip1, nor have we seen alterations in overall PP2A activity in egg extracts supplemented with Aven (data not shown). It has also been reported that protein phosphatase 5 (PP5) is required for ATM activation, so it is plausible that Aven could activate PP5 or inactivate a PP5 inhibitor [51] .
A Positive Feedback Loop Linking ATM and Aven Depletion of Aven in both mammalian and Xenopus systems compromised DNA-damage-induced ATM activation, and overexpression of Aven prevented mitotic entry in egg extracts. We propose that overexpression of Aven mimics a signaling pathway that would normally be engaged after DNA damage. After ATM activation by DSB or Aven overproduction, ATM may then phosphorylate Aven, enhancing Aven-mediated (D) GST-DN72hAven WT or S135, 153, 268, 308A protein was incubated in interphase extracts -(left) or + (middle and right) DSB DNA. After incubation, the protein was retrieved on glutathione Sepharose beads and resolved by SDS-PAGE, and the relevant bands were excised from the gel, trypsin digested, and analyzed by LC/MS mass spectrometry. LC/MS-extracted ion chromatograms (EIC) of unphosphorylated (0xP) and presumed monophosphorylated (1xP) tryptic peptides were examined, and EIC peaks (middle; at 2.6 and 11.5 min in the 1xP traces) indicate the phosphorylation of the tryptic peptides upon DSB DNA treatment. Such peaks were not detected in the tryptic peptides derived from the GST-AN72hAven S135, 153, 268, 308A protein (right), indicating a lack of phosphorylation. (E) Left panel: xATM kinase was immunoprecipitated from interphase extracts pretreated with DSB. Purified GST-DN72hAven WT or AQ mutant proteins were incubated with the immunoprecipitates in the kinase buffer for 30 min and assayed as (A). Right panel: the amount of Aven SQ phosphorylation was quantified, normalized, and plotted. Error bars represent standard deviation of three replicate experiments (t test, p < 0.05). (F) mRNA-encoding DN72hAven or DN72h-AvenS135, 308A was added to the cycling extracts, and aliquots were taken at the indicated times and immunoblotted with anti-pCdc2Y15 antibody.
ATM activation. After DNA damage, it might be that low-level ATM activation promotes Aven phosphorylation, leading to higher ATM activation. The impaired ability of the SQ mutant Aven to promote cell-cycle arrest and ATM activation is consistent with a role for these SQ phosphorylation sites in controlling Aven function.
Although Aven could be phosphorylated by ATM, basal phosphorylation of Aven was also evident when we incubated GST-Aven protein with egg extracts. Mass-spectrometric analysis of Aven dipped into egg extracts demonstrated basal phosphorylation on Ser and Thr sites, in addition to the SQ sites mentioned here (J.Y.G., M.Z.W., and S.K., unpublished data). Thus, other kinases and/or pathways might contribute to Aven phosphorylation, potentially providing additional inputs to Aven regulation.
A Dual Regulator of Cell-Cycle and Apoptotic Progression Although Aven was reported as an apoptotic regulator, we do not know whether its cell-cycle-and apoptotic-modulatory properties stem from the same underlying biochemical activity. It would be interesting to determine whether ATM is required for Aven's modulation of the apoptosome. Conversely, it will be of interest to determine whether Aven mutants that cannot modulate apoptosis can influence cell-cycle progression. Aven might require entirely different domains and/or functions to regulate cell division and apoptosis. In this regard, it is of interest that Apaf-1 was recently reported to induce S-phase arrest after DNA damage [52] . Although Aven has been shown to be an apoptosome regulator and Apaf-1 interactor ( [36] and P.M.I. and J.M.H., unpublished data), Apaf-1 was reported not to be required for ATM S1981 phosphorylation and activation, whereas Aven binds ATM and promotes its activation. Thus, Aven and Apaf-1 might act at different points in checkpoint control. Indeed, it could be that Apaf-1 is required for the intra-S phase but not for the G2/M checkpoint. It would be of significant interest to determine whether extensive DNA damage alleviates Aven's apoptotic-inhibitory functions. Regardless of its precise mechanism of action, Aven is ideally situated, as a mediator of both cell-cycle progression and cell death, to participate in the cellular decision to live or die after DNA damage.
Supplemental Data
Experimental Procedures and ten supplemental figures are available online at http://www.current-biology.com/cgi/content/full/18/13/933/DC1/. During DNA damage, Aven serves as a signal transducer in the ATM activation pathway. Activated ATM in turn phosphorylates Aven on S135 and S308, and causes full activation of Aven. Fully activated Aven then further enhances ATM activation, leading to activation of downstream pathway components to inhibit Cdc25 activation and enhance Wee1/Myt kinase activity, leading to Cdc2/CyclinB inactivation and inhibition of mitotic entry.
